• Nathalie Boiret-Dupré, Stéphane Descamps, Marie Ange Coudoré, Chantal Rapatel, Mathieu Kuentz, Sylvie Pereira, Josiane Tournadre, Juliette Berger, Philippe Morell, and Marc G Berger.
• Service d'Hématologie Biologique-Immunologie, CHU, Clermont-Ferrand, France.
• Clin Ther. 2009 Dec 1; 31 (12): 2900-4.

ObjectiveThis letter reports on the effect of enzyme replacement therapy with imiglucerase on bone healing and bone and blood abnormalities in a woman with previously untreated type 1 Gaucher disease (GD).MethodsThe 49-year-old patient had been diagnosed with GD at the age of 28 years and had previously undergone splenectomy. She presented with pseudarthrosis 14 months after sustaining a traumatic fracture of the tibia and fibula. Therapy was begun with imiglucerase 60 U/kg q2wk. The effects of treatment on bone healing were monitored radiographically, and effects on blood and bone marrow biology were monitored by hemograms, myelograms, and hematopoietic and mesenchymal clonogenic assays.ResultsObjective bone healing was observed starting in the third month of imiglucerase treatment. Blood abnormalities normalized and bone marrow parameters improved over the first 9 months, including a decrease in Gaucher cells, an increase in bone marrow CD34+ cell cloning efficiency, and the appearance of mesenchymal progenitors.ConclusionThis research letter reports the results of hematologic and bone evaluations during enzyme replacement therapy with imiglucerase in a woman with previously untreated type 1 GD who presented with a traumatic fracture.Copyright 2009 Excerpta Medica Inc. All rights reserved.

36 keywords...

hide…